


PRODUCT INFORMATION



Quizartinib

Item No. 17986

CAS Registry No.: 950769-58-1
Formal Name: N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-urea
Synonym: AC220
MF: C₂₉H₃₂N₆O₄S
FW: 560.7
Purity: ≥98%
UV/Vis.: λ_{max}: 295 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Quizartinib is supplied as a crystalline solid. A stock solution may be made by dissolving the quizartinib in the solvent of choice, which should be purged with an inert gas. Quizartinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of quizartinib in these solvents is approximately 0.25, 30, and 50 mg/ml, respectively.

Quizartinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, quizartinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Quizartinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Quizartinib is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; K_d = 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.^{1,2} It inhibits the proliferation of the human leukemia cell line MV4-11, which harbors a homozygous FLT3-ITD mutation, with an IC₅₀ value of 0.56 nM.¹ At 1 mg/kg/day, quizartinib has been shown to extend survival in a mouse model of FLT3-ITD acute myeloid leukemia and to eradicate tumors in an FLT3-dependent mouse xenograft model at 10 mg/kg.²

References

1. Chao, Q., Sprankle, K.G., Grotzfeld, R.M., *et al.* Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. *J. Med. Chem.* **52(23)**, 7808-7816 (2009).
2. Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., *et al.* AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). *Blood* **114(14)**, 2984-2992 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM